ClinicalTrials.gg

Program

Clomiphene

Also written as “Antioxidants + Clomiphene Citrate”, “Clomiphene Citrate 50 mg” and “Clomiphene Citrate 100 mg”.

Its studies are mostly in Oligospermia · Anovulation · Infertility, led by 3 companies.

Furthest: phase 4, since Sep 29, 20263 company-led studies, 1 open or runningNext primary completion: Oct 15, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hamad Medical11 open or runningphase 4since Sep 29, 2026Sep 29, 2026Oct 15, 2027phase 4 · NCT07862725
Merck KGaA, Darmstadt, Germany10 open or runningphase 2since Sep 13, 2005Sep 13, 2005none ahead
Midwest Fertility Specialists10 open or runningno phasesince Oct 1, 2014Oct 1, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 13, 2005First study: phase 2 study in AnovulationNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT00213148 · 271 enrolled · United States
  2. Oct 1, 2014Midwest Fertility Specialists's first study: no phase study in InfertilityNew to Midwest Fertility SpecialistsMidwest Fertility Specialists · NCT02294773 · 13 enrolled · United States
  3. Sep 29, 2026Hamad Medical's first study: phase 4 study in OligospermiaNew to Hamad MedicalHamad Medical · NCT07862725 · 360 planned · Qatar

Ahead

  1. Oct 15, 2027Primary completion: phase 4 study in OligospermiaHamad Medical · NCT07862725

TargetBeta

ESR1 →read by rule
“Estrogen receptor alpha modulator”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07862725Oligospermia · Qatar4Not yet recruitingHamad MedicalOct 15, 2027360
NCT02294773Infertility · United States–CompletedMidwest Fertility SpecialistsSep 201513
NCT00213148Anovulation · United States2CompletedMerck KGaA, Darmstadt, GermanyDec 12, 2007271

How it is read

Names in the registry

  • “Antioxidants + Clomiphene Citrate”, 1 entry
  • “Clomiphene Citrate 50 mg”, 1 entry
  • “Clomiphene Citrate 100 mg”, 1 entry
  • “Clomiphene”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.